Project Grant R21CA309231
Award Date 7/6/26
Completion Date 6/30/28
Dollars Obligated $396K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
- Federal Project Grant Award Summary Georgia TECH Research Corp will conduct integrated research to disrupt redox and lipid metabolic adaptations that confer radiotherapy resistance in head and neck cancer (HNC) patients. Funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) with $595,041 obligated, this five-year project (July 1, 2026–June 30, 2031) will deliver computational modeling, experimental validation, and preclinical testing services...
- Federal Project Grant Summary Ioncologi Inc. received a $276,544 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded September 1, 2025, with completion targeted for August 31, 2026. The award supports development of IOI7, an autologous, ex vivo-expanded immunomodulatory hematopoietic stem cell therapy designed to overcome immune checkpoint inhibitor resistance in relapsed or refractory glioblastoma. Phase 1 deliverables include...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Georgia TECH Research Corp a $705,899 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop antigen-presenting lipid nanoparticles (APLNs) for targeted delivery of B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) messenger RNA to specific immune effector cell subsets for multiple myeloma treatment. The award, effective June 1, 2026, through May 31, 2031, focuses on addressing...
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University a Project Grant of $702,132 under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics research focused on identifying small molecule modulators of glioblastoma immunogenicity. The project, which commenced June 11, 2026 and concludes May 31, 2029, will deliver high-throughput chemical transcriptomic profiling screening against 3,792 small molecules to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Georgia State University Research Foundation Inc. a $406,258 Project Grant on July 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop novel covalent anti-cancer drugs utilizing phosphorus fluoride exchange (PFEX) click chemistry. The two-year research initiative, concluding June 30, 2027, focuses on designing privileged covalent warheads with expanded target scopes to overcome limitations of...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded Georgia TECH Research Corp a $212,297 Project Grant effective July 1, 2026, through March 31, 2029, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). This Trailblazer project will deliver engineered stress-responsive protein sensors and synthetic biological circuits designed to sense and respond to physiological stress...
- Grant Award Summary Georgia TECH Research Corp received a $396,406 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded May 1, 2026, with completion targeted for April 30, 2029. The project will develop an In Vitro Human Intraductal (IHIND) model to advance early-stage breast cancer progression research using all-human cell systems in a high-throughput 384-well format. This model will recreate physiologically...
- Federal Project Grant Award Summary Emory University received a $158,899 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded June 20, 2025, with completion targeted for May 31, 2027. This award supports the development of an innovative Simultaneous Intensity Energy Modulation and Compensation (SIEMAC) optimization platform and integrated quality assurance (QA) system for conformal flash proton therapy treatment of central lung...
- Federal Grant Award Summary Grant Details: Funding Agency: National Cancer Institute (NCI) Federal Grant Program: Cancer Treatment Research (CFDA 93.395) Award Amount: $454,109.00 Award Date: July 3, 2026 Project Period: July 3, 2026 – June 30, 2028 Recipient: Dana-Farber Cancer Institute, Inc. (Boston, MA) Products and Services: Dana-Farber Cancer Institute will develop and test a novel immunotherapy approach that reprograms tumor-associated macrophages (TAMs)—immune cells that typically...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Southern California a $3,036,844 Project Grant on August 11, 2025, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate a wireless thermos-activator device for controllable solid tumor immunotherapy. The project addresses critical limitations in Chimeric Antigen Receptor (CAR) T cell therapy by creating a portable, patient-friendly alternative to MRI-guided...